Clinical Trials Browser

NETWORK × Urinary Bladder Neoplasms × durvalumab × Clear all

NCT03768570 2026-02-02

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms